Screener
BridgeBio Pharma BBIO PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Prepaid expenses and other current assets | 62,914 | 44,070 |
| Total current assets | 1,241,306 | 797,749 |
| Equity method investments | 61,529 | 79,972 |
| Property and equipment, net | 4,941 | 5,366 |
| Operating lease right-of-use assets | 17,226 | 8,149 |
| Intangible assets, net | 27,359 | 28,077 |
| Other assets | 18,620 | 16,712 |
| Total assets | $1,370,981 | $936,025 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's PP&E (net)?
- BridgeBio Pharma (BBIO) reported PP&E (net) of $4.94M in Q1 2026.
- How has BridgeBio Pharma's PP&E (net) changed year-over-year?
- BridgeBio Pharma's PP&E (net) decreased by 26.2% year-over-year, from $6.7M to $4.94M.
- What is the long-term trend for BridgeBio Pharma's PP&E (net)?
- Over 5 years (2020 to 2025), BridgeBio Pharma's PP&E (net) has grown at a -23.4% compound annual growth rate (CAGR), from $20.33M to $5.37M.
- What does PP&E (net) mean?
- Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.
Ask your AI about BridgeBio Pharma's pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude